J L Marshall

Summary

Affiliation: Georgetown University
Country: USA

Publications

  1. ncbi request reprint Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses
    J L Marshall
    Georgetown University Medical Center, Vincent T Lombardi Cancer Center, Washington, DC 20007, USA
    J Clin Oncol 18:3964-73. 2000
  2. ncbi request reprint Phase I trial of orally administered pentosan polysulfate in patients with advanced cancer
    J L Marshall
    Lombardi Cancer Research Center, Georgetown University Hospital, Washington, DC 20007, USA
    Clin Cancer Res 3:2347-54. 1997
  3. ncbi request reprint A safety and pharmacokinetic study of a mixed-backbone oligonucleotide (GEM231) targeting the type I protein kinase A by two-hour infusions in patients with refractory solid tumors
    H X Chen
    Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA
    Clin Cancer Res 6:1259-66. 2000
  4. ncbi request reprint A Phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer
    P Bhargava
    Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA
    Clin Cancer Res 5:1989-95. 1999
  5. ncbi request reprint A phase I and pharmacokinetic study of squalamine, a novel antiangiogenic agent, in patients with advanced cancers
    P Bhargava
    Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA
    Clin Cancer Res 7:3912-9. 2001
  6. pmc Bevacizumab use and risk of cardiovascular adverse events among elderly patients with colorectal cancer receiving chemotherapy: a population-based study
    H T Tsai
    Department of Oncology, Georgetown University Medical Center, Washington, DC 20007 2401, USA
    Ann Oncol 24:1574-9. 2013
  7. ncbi request reprint Phase I and pharmacokinetic study of two sequences of gemcitabine and docetaxel administered weekly to patients with advanced cancer
    P Bhargava
    Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA
    Cancer Chemother Pharmacol 48:95-103. 2001
  8. ncbi request reprint Detection of a mixed-backbone oligonucleotide (GEM 231) in liver and tumor tissues by capillary electrophoresis
    R Bansal
    Department of Pharmacology, Georgetown University Medical Center, Washington, DC 20007, USA
    J Chromatogr B Biomed Sci Appl 750:129-35. 2001
  9. pmc The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-beta signaling
    L Lin
    Cancer Genetics, Digestive Diseases, and Developmental Molecular Biology, Department of Surgery, Georgetown University, Washington, DC 20007, USA
    Oncogene 28:961-72. 2009
  10. ncbi request reprint Capecitabine in colorectal cancer
    J L Marshall
    Lombardi Cancer Center, Georgetown University, Washington, DC, USA
    Oncology (Williston Park) 15:41-6; discussion 46-7. 2001

Collaborators

Detail Information

Publications11

  1. ncbi request reprint Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses
    J L Marshall
    Georgetown University Medical Center, Vincent T Lombardi Cancer Center, Washington, DC 20007, USA
    J Clin Oncol 18:3964-73. 2000
    ..This trial sought to determine, for the first time, the validity in human vaccinations of using two different recombinant vaccines in diversified prime-and-boost regimens to enhance T-cell responses to a tumor antigen...
  2. ncbi request reprint Phase I trial of orally administered pentosan polysulfate in patients with advanced cancer
    J L Marshall
    Lombardi Cancer Research Center, Georgetown University Hospital, Washington, DC 20007, USA
    Clin Cancer Res 3:2347-54. 1997
    ..Subsequent murine experiments showed PPS to be more effective as an anticancer agent when it is given intermittently. We propose a study of PPS given on a weekly schedule in further clinical trials...
  3. ncbi request reprint A safety and pharmacokinetic study of a mixed-backbone oligonucleotide (GEM231) targeting the type I protein kinase A by two-hour infusions in patients with refractory solid tumors
    H X Chen
    Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA
    Clin Cancer Res 6:1259-66. 2000
    ....
  4. ncbi request reprint A Phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer
    P Bhargava
    Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA
    Clin Cancer Res 5:1989-95. 1999
    ..v over 4 h. The principal DLT was neurotoxicity, which appeared to be dose-related and was completely reversible. On the basis of the short plasma t(1/2) of TNP-470, exploration of a prolonged i.v. infusion schedule is warranted...
  5. ncbi request reprint A phase I and pharmacokinetic study of squalamine, a novel antiangiogenic agent, in patients with advanced cancers
    P Bhargava
    Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA
    Clin Cancer Res 7:3912-9. 2001
    ..v. infusion every two weeks; and (b) to obtain information on prolonged (>120-h) continuous i.v. infusions in patients who have tolerated 120-h infusions...
  6. pmc Bevacizumab use and risk of cardiovascular adverse events among elderly patients with colorectal cancer receiving chemotherapy: a population-based study
    H T Tsai
    Department of Oncology, Georgetown University Medical Center, Washington, DC 20007 2401, USA
    Ann Oncol 24:1574-9. 2013
    ..Cardiovascular risk attributable to bevacizumab (Avastin(®), BEV) for treatment of metastatic colorectal cancer (CRC) remains unclear. We conducted a population-based cohort study to assess the safety of BEV use among patients aged ≥ 65...
  7. ncbi request reprint Phase I and pharmacokinetic study of two sequences of gemcitabine and docetaxel administered weekly to patients with advanced cancer
    P Bhargava
    Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA
    Cancer Chemother Pharmacol 48:95-103. 2001
    ..Minimally pretreated patients tolerated higher doses of this combination without significant toxicities. This schedule and combination demonstrated activity in a variety of solid tumors, and merits further evaluation...
  8. ncbi request reprint Detection of a mixed-backbone oligonucleotide (GEM 231) in liver and tumor tissues by capillary electrophoresis
    R Bansal
    Department of Pharmacology, Georgetown University Medical Center, Washington, DC 20007, USA
    J Chromatogr B Biomed Sci Appl 750:129-35. 2001
    ..Assay validation studies revealed that CE method is reproducible and specific for the determination of GEM 231 in tissue homogenates with a run time of less than 5 min...
  9. pmc The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-beta signaling
    L Lin
    Cancer Genetics, Digestive Diseases, and Developmental Molecular Biology, Department of Surgery, Georgetown University, Washington, DC 20007, USA
    Oncogene 28:961-72. 2009
    ..Thus, IL6/STAT3, a major signaling pathway in HCC stem cell renewal and proliferation, can provide a novel approach to the treatment of specific HCCs...
  10. ncbi request reprint Capecitabine in colorectal cancer
    J L Marshall
    Lombardi Cancer Center, Georgetown University, Washington, DC, USA
    Oncology (Williston Park) 15:41-6; discussion 46-7. 2001
    ....
  11. ncbi request reprint Novel strategies in cancer therapeutics: targeting enzymes involved in cell cycle regulation and cellular proliferation
    M C Liu
    Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, 3800 Reservoir Rd NW, Washington, DC 20007, USA
    Curr Cancer Drug Targets 4:403-24. 2004
    ....